These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 29844056)

  • 1. Clinical Pharmacology in HIV Therapy.
    Atta MG; De Seigneux S; Lucas GM
    Clin J Am Soc Nephrol; 2019 Mar; 14(3):435-444. PubMed ID: 29844056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The road to success. Long-term prognosis for persons living with HIV in Denmark - time trends and risk factors.
    Lohse N
    Dan Med J; 2016 Feb; 63(2):. PubMed ID: 26836803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Odefsey--another NNRTI combination for HIV.
    Med Lett Drugs Ther; 2016 May; 58(1494):60-1. PubMed ID: 27148923
    [No Abstract]   [Full Text] [Related]  

  • 4. Cabotegravir/rilpivirine (Cabenuva) for HIV-1 infection.
    Med Lett Drugs Ther; 2021 May; 63(1625):81-83. PubMed ID: 34180282
    [No Abstract]   [Full Text] [Related]  

  • 5. Drug safety evaluation profile of stavudine plus lamivudine for HIV-1/AIDS infection.
    Mateo MG; Gutierrez Mdel M; Vidal F; Domingo P
    Expert Opin Drug Saf; 2012 May; 11(3):473-85. PubMed ID: 22468613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term safety and tolerability of the lamivudine/abacavir combination as components of highly active antiretroviral therapy.
    Castillo SA; Hernandez JE; Brothers CH
    Drug Saf; 2006; 29(9):811-26. PubMed ID: 16944966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Practical issues regarding the use of antiretroviral therapy for HIV infection.
    Deeks SG
    West J Med; 1998 Feb; 168(2):133-9. PubMed ID: 9499754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of abacavir/lamivudine with raltegravir in treatment-experienced and treatment-naïve patients with HIV-1 infection: an observational, retrospective, multi-centre study.
    Rizzardo S; Lanzafame M; Lattuada E; Bragantini D; Nicolè S; Calza L; Tacconelli E
    Int J STD AIDS; 2019 Apr; 30(5):467-471. PubMed ID: 30999834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel antiretroviral combinations in treatment-experienced patients with HIV infection: rationale and results.
    Taiwo B; Murphy RL; Katlama C
    Drugs; 2010 Sep; 70(13):1629-42. PubMed ID: 20731472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Antiretroviral drugs 1998/1999].
    Rieger A
    Wien Med Wochenschr; 1998; 148(23-24):567-76. PubMed ID: 10189688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV disease and advanced age: an increasing therapeutic challenge.
    Manfredi R
    Drugs Aging; 2002; 19(9):647-69. PubMed ID: 12381235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The future of antiretroviral therapy: challenges and needs.
    Moreno S; López Aldeguer J; Arribas JR; Domingo P; Iribarren JA; Ribera E; Rivero A; Pulido F;
    J Antimicrob Chemother; 2010 May; 65(5):827-35. PubMed ID: 20228080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Consensus document of Gesida and Spanish Secretariat for the National Plan on AIDS (SPNS) regarding combined antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2012)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2012 Jun; 30(6):e1-89. PubMed ID: 22633764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens.
    Patel N; Abdelsayed S; Veve M; Miller CD
    Ann Pharmacother; 2011 Mar; 45(3):317-24. PubMed ID: 21386025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacologic perspectives for once-daily antiretroviral therapy.
    Anderson PL
    Ann Pharmacother; 2004 Nov; 38(11):1924-34. PubMed ID: 15479772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. "Solving the puzzle" of current HAART: what key strategic trials are needed?
    Carosi G; Torti C
    New Microbiol; 2004 Apr; 27(2 Suppl 1):127-30. PubMed ID: 15646075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Antiretroviral therapy].
    von Braun A; Furrer H; Battegay M; Calmy A; Cavassini M; Vernazza P; Bernasconi E; Weber R; Günthard HF
    Ther Umsch; 2014 Aug; 71(8):461-8. PubMed ID: 25093310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Using pharmacokinetics to optimize antiretroviral drug-drug interactions in the treatment of human immunodeficiency virus infection.
    Gerber JG
    Clin Infect Dis; 2000 Jun; 30 Suppl 2():S123-9. PubMed ID: 10860896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacologic consideration for the use of antiretroviral agents in the elderly.
    Rhee MS; Greenblatt DJ
    J Clin Pharmacol; 2008 Oct; 48(10):1212-25. PubMed ID: 18812611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.